Comparing the effectiveness of different vaccination regimens using Sinovac and BNT162b2 vaccines among hospitalised patients: A single-centre hospital-based retrospective cohort study

Abstract

Objectives: This study aimed to assess the effectiveness of different vaccination regimens using two distinct SARS-CoV-2 vaccines against mortality risk and the need for intensive care unit (ICU) admission among hospitalised patients.

Methods: The single-centre hospital-based retrospective cohort study was performed with adult COVID-19 patients in a tertiary-level hospital between March 2020 and September 2022. The associations between patients’ demographics and clinical features, vaccine status and regimens, in-hospital mortality, and need for ICU admission were evaluated using multivariable regression analyses.

Results: During the study period, 2,373 patients were included. Mortality among unvaccinated patients was 85.0%, which was significantly lower in vaccinated groups (P<0.001), particularly with BNT162b2 than with Sinovac. Vaccination reduced mortality and ICU admission rates, with higher efficacy observed with increased vaccine doses and BNT162b2 regimens. Multivariable analyses confirmed age as a significant determinant and various vaccination schedules showed consistent reductions in mortality and ICU admissions.

Conclusions: A two-dose initial plus one or more-dose booster BNT162b2 regimen effectively reduced mortality risks and ICU admission.

Keywords

• COVID-19
• vaccine
• mortality
• intensive care unit

Ethical Statement

This study was approved by the University of Health Sciences, Bursa Yüksek Ihtisas Training and Research Hospital, Clinical Research Ethics Committee (Decision no. 2011-KAEK-25 2022/04-18, date: 20.04.2022).

References

1. 1. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) - China, 2020. China CDC Wkly. 2020.2(8):113-122.
2. 2. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A Novel Coronavirus Emerging in China-Key Questions for Impact Assessment. N Engl J Med. 2020.382(8):692-694. doi: 10.1056/NEJMp2000929.
3. 3. Stöhr K. Influenza--WHO cares. Lancet Infect Dis. 2002.2(9):517. doi: 10.1016/s1473-3099(02)00366-3.
4. 4. Girard MP, Cherian T, Pervikov Y, Kieny MP. A review of vaccine research and development: human acute respiratory infections. Vaccine. 2005.23(50):5708-5724. doi: 10.1016/j.vaccine.2005.07.046.
5. 5. Lotfi H, Mazar MG, Ei NMH, Fahim M, Yazdi NS. Vaccination is the most effective and best way to avoid the disease of COVID-19. Immun Inflamm Dis. 2023;11(8):e946. doi: 10.1002/iid3.946.
6. 6. Kitabatake M, Ouji-Sageshima N, Sonobe S, et al. Transition of Antibody Titers after SARS-CoV-2 mRNA Vaccination in Japanese Healthcare Workers. Jpn J Infect Dis. 2023;76(1):72-76. doi: 10.7883/yoken.JJID.2022.041.
7. 7. Alshanqeeti S, Szpunar S, Anne P, Saravolatz L, Bhargava A. Epidemiology, clinical features and outcomes of hospitalized patients with COVID-19 by vaccination status: a multicenter historical cohort study. Virol J. 2024;21(1):71. doi: 10.1186/s12985-024-02325-x.
8. 8. Prokop M, van Everdingen W, van Rees Vellinga T, et al; COVID-19 Standardized Reporting Working Group of the Dutch Radiological Society. CO-RADS: A Categorical CT Assessment Scheme for Patients Suspected of Having COVID-19-Definition and Evaluation. Radiology. 2020;296(2):E97-104. doi: 10.1148/radiol.2020201473.

9. 9. Bajaj K, Rathee P, Jain P, Panwar VR. Comparison of the Reliability of Anatomic Landmarks based on PA Cephalometric Radiographs and 3D CT Scans in Patients with Facial Asymmetry. Int J Clin Pediatr Dent. 2011;4(3):213-223. doi: 10.5005/jp-journals-10005-1112.
10. 10. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(24):759-765. doi: 10.15585/mmwr.mm6924e2.
11. 11. Jin JM, Bai P, He W, et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. Front Public Health. 2020;8:152. doi: 10.3389/fpubh.2020.00152.
12. 12. Finelli L, Gupta V, Petigara T, Yu K, Bauer KA, Puzniak LA. Mortality Among US Patients Hospitalized With SARS-CoV-2 Infection in 2020. JAMA Netw Open. 2021;4(4):e216556. doi: 10.1001/jamanetworkopen.2021.6556.
13. 13. Akkiz H. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern. Front Med (Lausanne). 2022;9:849217. doi: 10.3389/fmed.2022.849217.
14. 14. Yuan Y, Jiao B, Qu L, Yang D, Liu R. The development of COVID-19 treatment. Front Immunol. 2023;14:1125246. doi: 10.3389/fimmu.2023.1125246.
15. 15. Bhargava A, Sharma M, Riederer K, Fukushima EA, Szpunar SM, Saravolatz L. Risk Factors for In-hospital Mortality from Coronavirus Disease 2019 Infection Among Black Patients-An Urban Center Experience. Clin Infect Dis. 2021;73(11):e4005-11. doi: 10.1093/cid/ciaa1468.
16. 16. Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022;28(2):202-221. doi: 10.1016/j.cmi.2021.10.005.
17. 17. Yildirim S, Kirakli C, Ozdemir Y, et al. Impact of vaccination on ICU admissions of hospitalized COVID-19 patients in a country with a heterologous vaccine policy. J Infect Dev Ctries. 2024;18(4):513-519. doi: 10.3855/jidc.18342.
18. 18. Moline HL, Whitaker M, Deng L, et al. Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years - COVID-NET, 13 States, February-April 2021. MMWR Morb Mortal Wkly Rep. 2021;70(32):1088-1093. doi: 10.15585/mmwr.mm7032e3.
19. 19. Gholinataj Jelodar M, Mirzaei S, Saghafi F, et al. Impact of vaccination status on clinical outcomes of hospitalized COVID-19 patients. BMC Infect Dis. 2024;24(1):254. doi: 10.1186/s12879-024-09139-w.
20. 20. Tenforde MW, Self WH, Adams K, et al; Influenza and Other Viruses in the Acutely Ill (IVY) Network. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA. 2021;326(20):2043-2054. doi: 10.1001/jama.2021.19499.
21. 21. Liu W, Yang C, Liao YG, et al. Risk factors for COVID-19 progression and mortality in hospitalized patients without pre-existing comorbidities. J Infect Public Health. 2022;15(1):13-20. doi: 10.1016/j.jiph.2021.11.012.
22. 22. Gul F, Kasapoglu US, Sabaz MS, et al. The Impact of CoronaVac Vaccination on 28-day Mortality Rate of Critically Ill Patients with COVID-19 in Turkiye. Balkan Med J. 2023;40(6):435-444. doi: 10.4274/balkanmedj.galenos.2023.2023-6-90.
23. 23. Soheili M, Khateri S, Moradpour F, et al. The efficacy and effectiveness of COVID-19 vaccines around the world: a mini-review and meta-analysis. Ann Clin Microbiol Antimicrob. 2023;22(1):42. doi: 10.1186/s12941-023-00594-y.